Ketamine in Pain Management

CNS Neuroscience and Therapeutics

Volumn 19, Issue 6, 2013, Pages 396-402

  Persson, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ketamine; Pain management

Indexed keywords

ACETYLCHOLINE; INTERLEUKIN 6; KETAMINE; LOCAL ANESTHETIC AGENT; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; OPIATE AGONIST; PHENCYCLIDINE; PLACEBO; PSYCHEDELIC AGENT; SIGMA OPIATE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANALGESIA; ANALGESIC ACTIVITY; ANESTHESIA; ANTERIOR CINGULATE; ANTIINFLAMMATORY ACTIVITY; CANCER PAIN; CHRONIC PAIN; CINGULATE GYRUS; CLINICAL CLASSIFICATION; FIBROMYALGIA; FOLLOW UP; GUINEA PIG; HUMAN; IN VITRO STUDY; INSULA; INTRACTABLE PAIN; INTRAVENOUS REGIONAL ANESTHESIA; LONG TERM CARE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PALLIATIVE THERAPY; PERIOPERATIVE PERIOD; PHANTOM PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; REVIEW; SECONDARY SOMATOSENSORY CORTEX; SEROTONIN UPTAKE; THALAMUS;

ANALGESICS; ANIMALS; HUMANS; KETAMINE; PAIN; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID;

EID: 84878124776     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12111     Document Type: Review

References (90)

1. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965;6:279-291.
2. Aroni F, Iacovidou N, Dontas I, Pourzitaki C, Xanthos T. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. J Clin Pharmacol 2009;49:957-964.
3. Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 1966;45:29-40.
4. Harden RN. Ketamine analgesia: a call for better science. Pain Med 2012;13:145-147.
5. Green SM, Krauss B. The semantics of ketamine. Ann Emerg Med 2000;36:480-482.
6. Sadove MS, Shulman M, Hatano S, Fevold N. Analgesic effects of ketamine administered in subdissociative doses. Anesth Analg 1971;50:452-457.
7. Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 1990;11:81-86.
8. Foster AC, Fagg GE. Neurobiology. Taking apart NMDA receptors. Nature 1987;329:395-396.
9. Lodge D, Anis NA, Burton NR. Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine. Neurosci Lett 1982;29:281-286.
10. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992;260:1209-1213.
11. Klepstad P, Maurset A, Moberg ER, Oye I. Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 1990;187:513-518.
12. Lois F, De Kock M. Something new about ketamine for pediatric anesthesia? Curr Opin Anaesthesiol 2008;21:340-344.
13. Finck AD, Ngai SH. Opiate receptor mediation of ketamine analgesia. Anesthesiology 1982;56:291-297.
14. Smith DJ, Pekoe GM, Martin LL, Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci 1980;26:789-795.
15. Smith DJ, Bouchal RL, deSanctis CA, et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 1987;26:1253-1260.
16. Finck AD, Samaniego E, Ngai SH. Morphine tolerance decreases the analgesic effects of ketamine in mice. Anesthesiology 1988;68:397-400.
17. Hustveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 1995;77:355-359.
18. Maurset A, Skoglund LA, Hustveit O, Oye I. Comparison of ketamine and pethidine in experimental and postoperative pain. Pain 1989;36:37-41.
19. Stella L, Crescenti A, Torri G. Effect of naloxone on the loss of consciousness induced by i.v. anaesthetic agents in man. Br J Anaesth 1984;56:369-373.
20. Amiot JF, Bouju P, Palacci JH. Effect of naloxone on loss of consciousness induced by i.v. ketamine. Br J Anaesth 1985;57:930.
21. Chapman V, Dickenson AH. The combination of NMDA antagonism and morphine produces profound antinociception in the rat dorsal horn. Brain Res 1992;573:321-323.
22. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999;82:111-125.
23. Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2003;CD003351.
24. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2012;11:CD003351.
25. Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30:3611-3617.
26. Weber WV, Jawalekar KS, Jawalekar SR. The effect of ketamine on nerve conduction in isolated sciatic nerves of the toad. Neurosci Lett 1975;1:115-120.
27. Durrani Z, Winnie AP, Zsigmond EK, Burnett ML. Ketamine for intravenous regional anesthesia. Anesth Analg 1989;68:328-332.
28. Frenkel C, Urban BW. Molecular actions of racemic ketamine on human CNS sodium channels. Br J Anaesth 1992;69:292-297.
29. Leonard BE. Sigma receptors and sigma ligands: background to a pharmacological enigma. Pharmacopsychiatry 2004;37(Suppl 3):S166-S170.
30. Abelson KS, Goldkuhl RR, Nylund A, Hoglund AU. The effect of ketamine on intraspinal acetylcholine release: involvement of spinal nicotinic receptors. Eur J Pharmacol 2006;534:122-128.
31. Durieux ME. Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg 1995;81:57-62.
32. Crisp T, Perrotti JM, Smith DL, Stafinsky JL, Smith DJ. The local monoaminergic dependency of spinal ketamine. Eur J Pharmacol 1991;194:167-172.
33. Martin LL, Smith DJ. Ketamine inhibits serotonin synthesis and metabolism in vivo. Neuropharmacology 1982;21:119-125.
34. Koizuka S, Obata H, Sasaki M, Saito S, Goto F. Systemic ketamine inhibits hypersensitivity after surgery via descending inhibitory pathways in rats. Can J Anaesth 2005;52:498-505.
35. Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol 2009;7:331-336.
36. Hartvig P, Valtysson J, Lindner KJ, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995;58:165-173.
37. Sprenger T, Valet M, Woltmann R, et al. Imaging pain modulation by subanesthetic S-(+)-ketamine. Anesth Analg 2006;103:729-737.
38. Rogers R, Wise RG, Painter DJ, Longe SE, Tracey I. An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. Anesthesiology 2004;100:292-301.
39. Niesters M, Khalili-Mahani N, Martini C, et al. Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers. Anesthesiology 2012;117:868-877.
40. Akata T, Izumi K, Nakashima M. Mechanisms of direct inhibitory action of ketamine on vascular smooth muscle in mesenteric resistance arteries. Anesthesiology 2001;95:452-462.
41. Wong BS, Martin CD. Ketamine inhibition of cytoplasmic calcium signalling in rat pheochromocytoma (PC-12) cells. Life Sci 1993;53:PL359-PL364.
42. Seeman P, Guan HC, Hirbec H. Dopamine D2 High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 2009;63:698-704.
43. Mazar J, Rogachev B, Shaked G, et al. Involvement of adenosine in the antiinflammatory action of ketamine. Anesthesiology 2005;102:1174-1181.
44. Wu GJ, Chen TL, Ueng YF, Chen RM. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol 2008;228:105-113.
45. Uzaraga I, Gerbis B, Holwerda E, Gillis D, Wai E. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study. Support Care Cancer 2012;20:1515-1524.
46. Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine. Pain 2009;146:18-25.
47. Pedersen JL, Galle TS, Kehlet H. Peripheral analgesic effects of ketamine in acute inflammatory pain. Anesthesiology 1998;89:58-66.
48. Persson J. Wherefore ketamine? Curr Opin Anaesthesiol 2010;23:455-460.
49. Arendt-Nielsen L, Petersen-Felix S, Fischer M, Bak P, Bjerring P, Zbinden AM. The effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. Anesth Analg 1995;81:63-68.
50. Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth 1996;77:441-444.
51. Chizh BA. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol 2007;21:259-271.
52. Knox JW, Bovill JG, Clarke RS, Dundee JW. Clinical studies of induction agents. VI: Ketamine. Br J Anaesth 1970;42:875-885.
53. Yusuke I. Postoperative pain relief with ketamine infusion. Anaesthesia 1974;29:222.
54. Wallace PG, Norris W. The management of postoperative pain. Br J Anaesth 1975;47:113-120.
55. White PF, Way WL, Trevor AJ. Ketamine - its pharmacology and therapeutic uses. Anesthesiology 1982;56:119-136.
56. Bell RF, Dahl JB, Moore RA, Kalso E. Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand 2005;49:1405-1428.
57. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998;87:1186-1193.
58. Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology 2002;96:725-741.
59. Yaksh TL, Tozier N, Horais KA, et al. Toxicology profile of N-methyl-D-aspartate antagonists delivered by intrathecal infusion in the canine model. Anesthesiology 2008;108:938-949.
60. Green SM, Cote CJ. Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. Ann Emerg Med 2009;54:181-190.
61. El Shobary HM, Sonbul ZM, Schricker TP. Epidural ketamine for postoperative analgesia in the elderly. Middle East J Anesthesiol 2008;19:1369-1378.
62. Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth 2011;58:911-923.
63. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004;99:482-495, table of contents.
64. Persson J. The ketamine enigma. Acta Anaesthesiol Scand 2008;52:453-455.
65. Berti M, Baciarello M, Troglio R, Fanelli G. Clinical uses of low-dose ketamine in patients undergoing surgery. Curr Drug Targets 2009;10:707-715.
66. Carstensen M, Moller AM. Adding ketamine to morphine for intravenous patient-controlled analgesia for acute postoperative pain: a qualitative review of randomized trials. Br J Anaesth 2010;104:401-406.
67. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006;367:1618-1625.
68. Svenson JE, Abernathy MK. Ketamine for prehospital use: new look at an old drug. Am J Emerg Med 2007;25:977-980.
69. Bion JF. Infusion analgesia for acute war injuries. A comparison of pentazocine and ketamine. Anaesthesia 1984;39:560-564.
70. Cottingham R, Thomson K. Use of ketamine in prolonged entrapment. J Accid Emerg Med 1994;11:189-191.
71. Pal SK, Cortiella J, Herndon D. Adjunctive methods of pain control in burns. Burns 1997;23:404-412.
72. McGuinness SK, Wasiak J, Cleland H, et al. A systematic review of ketamine as an analgesic agent in adult burn injuries. Pain Med 2011;12:1551-1558.
73. Porter K. Ketamine in prehospital care. Emerg Med J 2004;21:351-354.
74. Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg 2003;96:789-795, table of contents.
75. Kochs E, Scharein E, Mollenberg O, Bromm B, Schulte am Esch J. Analgesic efficacy of low-dose ketamine. Somatosensory-evoked responses in relation to subjective pain ratings. Anesthesiology 1996;85:304-314.
76. Wedmore IS, Johnson T, Czarnik J, Hendrix S. Pain management in the wilderness and operational setting. Emerg Med Clin North Am 2005;23:585-601, xi-xii.
77. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 1994;56:51-57.
78. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000;20:358-373.
79. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003;97:1730-1739.
80. Bell RF. Ketamine for chronic non-cancer pain. Pain 2009;141:210-214.
81. Prommer EE. Ketamine for pain: an update of uses in palliative care. J Palliat Med 2012;15:474-483.
82. Oshima E, Tei K, Kayazawa H, Urabe N. Continuous subcutaneous injection of ketamine for cancer pain. Can J Anaesth 1990;37:385-386.
83. Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 1999;17:296-300.
84. Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage 2003;26:867-875.
85. Lam DK, Dang D, Zhang J, Dolan JC, Schmidt BL. Novel animal models of acute and chronic cancer pain: a pivotal role for PAR2. J Neurosci 2012;32:14178-14183.
86. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206.
87. MacKintosh D, Brady A, Carr S. Ketamine: a real-world experience in cancer pain. J Palliat Med 2012;15:733.
88. Sigtermans M, Noppers I, Sarton E, et al. An observational study on the effect of S + -ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. Eur J Pain 2010;14:302-307.
89. Mercadante S, Villari P, Ferrera P, Arcuri E, David F. Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases. Clin J Pain 2009;25:648-649.
90. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Pharm Des 2005;11:2977-2994.